Evidence map›Paper›PMID 29668565›Full record

ArticleShock (Augusta, Ga.)2019

The Effects of Genetic 3-Mercaptopyruvate Sulfurtransferase Deficiency in Murine Traumatic-Hemorrhagic Shock.

Michael Gröger, Martin Wepler, Ulrich Wachter, Tamara Merz, Oscar McCook, Sandra Kress, Britta Lukaschewski, Sebastian Hafner, Markus Huber-Lang, Enrico Calzia and 5 more

Abstract read
In one paragraph

Article in Shock (Augusta, Ga.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. HIntensive care medicine experimental · 2020
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 3 countries.

Michael GrögerInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Martin WeplerInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Ulrich WachterInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Tamara MerzInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Oscar McCookInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Sandra KressInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Britta LukaschewskiInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Sebastian HafnerInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Markus Huber-LangInstitute of Clinical and Experimental Trauma Immunology, University Hospital, Ulm, Germany.
Enrico CalziaInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Michael GeorgieffDepartment of Anesthesiology, University Hospital, Ulm, Germany.
Noriyuki NagaharaIsotope Research Centre, Nippon Medical School, Tokyo, Japan.
Csaba SzabóDepartment of Anesthesiology, University of Texas Medical Branch, Galveston, Texas.
Peter RadermacherInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
Clair HartmannInstitute of Anesthesiological Pathophysiology and Process Engineering, University Hospital, Ulm, Germany.
University Hospital Ulm · DENippon Medical School · JPThe University of Texas Medical Branch at Galveston · US

Funding

Regulation of cellular bioenergetics by hydrogen sulfideR01GM107846 · NIGMS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SZABO, CSABA · 2014 to 2017
$1.2M
NIGMS NIH HHS R01 GM107846
6 · The paper itself

Abstract

introductionHemorrhagic shock is a major cause of death after trauma. An additional blunt chest trauma independently contributes to mortality upon the development of an acute lung injury (ALI) by aggravating pathophysiological consequences of hemorrhagic shock. The maintenance of hydrogen sulfide availability is known to play an important role during hemorrhage and ALI. We therefore tested the impact of a genetic 3-mercaptopyruvate sulfurtransferase mutation (Δ3-MST) in a resuscitated murine model of traumatic-hemorrhagic shock.

methodsAnesthetized wild-type (WT) and Δ3-MST mice underwent hemorrhagic shock with/without blunt chest trauma. Hemorrhagic shock was implemented for 1 h followed by retransfusion of shed blood and intensive care therapy for 4 h, including lung-protective mechanical ventilation, fluid resuscitation, and noradrenaline titrated to maintain a mean arterial pressure at least 50 mmHg. Systemic hemodynamics, metabolism, and acid-base status were assessed together with lung mechanics and gas exchange. Postmortem tissue samples were analyzed for immunohistological protein expression and mitochondrial oxygen consumption.

results3-MST-deficient mice showed similar results in parameters of hemodynamics, gas exchange, metabolism, acid base status, and survival compared with the respective WT controls. Renal albumin extravasation was increased in Δ3-MST mice during hemorrhagic shock, together with a decrease of LEAK respiration in heart tissue. In contrast, mitochondrial oxygen consumption in the uncoupled state was increased in kidney and liver tissue of Δ3-MST mice subjected to the combined trauma.

conclusionsIn summary, in a resuscitated murine model of traumatic-hemorrhagic shock, 3-MST deficiency had no physiologically relevant impact on hemodynamics and metabolism, which ultimately lead to unchanged mortality regardless of an additional blunt chest trauma.

Indexed as

AnimalsCysteineDisease Models, AnimalFemaleImmunohistochemistryMaleMiceMitochondriaMutationShock, HemorrhagicShock, TraumaticSulfurtransferases3-mercaptopyruvate sulphurtransferase3-mercaptopyruvic acidCysteineSulfurtransferases

Identifiers

PMID29668565
PMCPMC6192867
OpenAlexW2799621282

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.